Analysis of AstraZeneca's IMFINZI (Durvalumab) for Treating Malignant Pleural Mesothelioma (MPM): Regulatory Landmarks, Market Expansion, Intellectual Property, Future Challenges - Forecast to 2032

Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "IMFINZI Emerging Drug Insight and Market Forecast - 2032" report has been added to's offering.

This comprehensive report offers a wealth of information on the prospects of durvalumab (IMFINZI) for the treatment of malignant pleural mesothelioma (MPM). This exhaustive analysis spans key markets across the United States, European Union, United Kingdom, and Japan, presenting a detailed forecast and current therapeutic landscape for the period through 2032.

IMFINZI, developed by AstraZeneca, is an innovative treatment option based on a human IgG1 kappa monoclonal antibody technology, targeting the PD-L1/PD-1 and PD-L1/CD80 pathways to enhance the immune response against cancer cells. With an international scope encompassing the pivotal regions of United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan, this report delivers a meticulous overview of IMFINZI's role in MPM treatment including crucial information on its mechanism of action, administration guidelines, and dosages backed by rigorous research and development insights, complete with key regulatory milestones. Current and prospective market dynamics and their implications for IMFINZI are scrutinized, with strategic SWOT analyses providing a clear picture of potential challenges and opportunities ahead.

Renowned for its robust methodologies, the report is the culmination of extensive data collection from recognized primary and secondary sources, expertly analyzed by seasoned industry specialists. With important clinical trial evaluations such as PrE0505 and DREAM3R shedding light on the efficacy and safety of IMFINZI, the document offers valuable information for healthcare stakeholders concerning trial conditions, interventions, statuses, alongside start and end dates.

Emerging Market Trends and Clinical Advancements in MPM:

  • Unveiling the intricate landscape of regulatory milestones and development activities surrounding IMFINZI.
  • Assessment of IMFINZI's potential expansion within the MPM treatment sector fueled by increasing healthcare expenditures and research.
  • Key insights into intellectual property and patent lifecycles essential to forecast and strategic planning.
  • Exploration of late-stage emerging therapies that are poised to challenge IMFINZI's market position.
  • Anticipated market performance of IMFINZI secured through projected sales data spanning from 2026 to 2032 in crucial markets.

The findings of the report suggest that IMFINZI is poised to play a significant role in the evolving MPM therapeutic landscape. With focused research, strategic collaborations, and emerging competition from novel therapies, the market forecast offers vital information for decision-makers in the pharmaceutical industry.

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.